Study summary

Cabozantinib more than tripled time before growth in pancreatic NETs

CABINET trial · Phase 3, double-blind · Published September 2024, New England Journal of Medicine; FDA approved 2025

13.8 mobefore growth in pancreatic NETs, vs 4.4 with placebo

What was tested

Cabozantinib, a multi-target pill, against placebo for advanced neuroendocrine tumors that grew after earlier treatment, in pancreatic and extrapancreatic groups.

What they found

Pancreatic NETs: 13.8 vs 4.4 months before growth.
Extrapancreatic NETs: 8.4 vs 3.9 months.
Side effects such as high blood pressure and fatigue were common.

What it means

Added a pill option after somatostatin drugs, everolimus or radioligand therapy.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.